While BACE1 inhibitors have been effective in the clinic to reduce Aβ40 and Aβ42 [64–66], unfortunately, such inhibitors have not significantly improved cognitive deficit of AD [64, 66]. Here, BACE1 is linked to Alzheimer disease.